Most Managed Care Insurers Expected To See Q2 2025 Drops In Revenue, Net Income
A majority of publicly traded US health insurers are expected to post QoQ declines in revenue and net income in Q2, according to an S&P Global Market Intelligence analysis of sell-side analyst forecasts. Of the eight largest publicly traded US managed care insurers, all but two — UnitedHealth Group and Alignment Healthcare — are projected to report lower revenue compared with Q1 2025, while all eight are forecast to log higher revenue than Q2 2024. In Q2, all eight of the largest publicly traded US managed care insurers, except The Cigna Group, are expected to log lower net income sequentially, while all eight are forecast to report lower net income YoY.
Alignment Healthcare (ALHC) Upgraded to Buy: Here's What You Should Know
Alignment Healthcare (ALHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
Here is how Alignment Healthcare (ALHC) and BridgeBio Pharma (BBIO) have performed compared to their sector so far this year.
Compared to Estimates, Alignment Healthcare (ALHC) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Alignment Healthcare (ALHC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates
Alignment Healthcare (ALHC) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.25 per share a year ago.
All You Need to Know About Alignment Healthcare (ALHC) Rating Upgrade to Buy
Alignment Healthcare (ALHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alignment Healthcare (ALHC) Surges 6.3%: Is This an Indication of Further Gains?
Alignment Healthcare (ALHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alignment Healthcare, Inc. (ALHC) Q4 2024 Earnings Call Transcript
Alignment Healthcare, Inc. (NASDAQ:ALHC ) Q4 2024 Results Conference Call February 27, 2025 5:00 PM ET Company Participants John Kao - Founder & Chief Executive Officer Thomas Freeman - Chief Financial Officer Conference Call Participants Scott Fidel - Stephens Adam Ron - Bank of America Michael Ha - Baird Matthew Gillmor - KeyBanc Capital Markets Jessica Tassan - Piper Sandler Operator Good afternoon, and welcome to Alignment Healthcare's Fourth Quarter 2024 Earnings Conference Call and Webcast. [Operator Instructions].
Compared to Estimates, Alignment Healthcare (ALHC) Q4 Earnings: A Look at Key Metrics
The headline numbers for Alignment Healthcare (ALHC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alignment Healthcare (ALHC) Reports Q4 Loss, Tops Revenue Estimates
Alignment Healthcare (ALHC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.25 per share a year ago.
Insights Into Alignment Healthcare (ALHC) Q4: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Alignment Healthcare (ALHC) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Focus On Costs, Regulatory Outlook For Health Insurers In Q4'24 Earnings Season
Most publicly traded US health insurers are forecast to report sequential revenue and earnings declines for the fourth quarter of 2024, according to S&P Global Market Intelligence analysis of sell-side analyst forecasts. Coming off a challenging end to 2024, the upcoming earnings season is an opportunity for managed care companies to focus on 2025 expectations and Medicare Advantage growth, according to J.P. Morgan analyst Lisa Gill. UnitedHealth and Oscar Health are expected to log sequential and year-over-year revenue growth.
